An experimental treatment has doubled one-year survival rates for pancreatic cancer, one of the deadliest types of cancer, a new study reports.
The drug, called elraglusib, targets the protective web that pancreatic tumors build around themselves, thus helping immune molecules and chemotherapy better penetrate the tumors. The results of the trial showing elraglusib's safety and efficacy were published April 14 in the journal Nature Medicine.
